Amgen forms new partnership with NHS Cancer Vanguard

Amgen has signed an agreement with the NHS Cancer Vanguard scheme, which is dedicated to trialling new methods of delivering cancer services.

Pharmaceutical companies were invited by the Cancer Vanguard to submit proposals to improve the availability and delivery of cancer drugs, with a total of 22 companies putting forward 39 proposals.

Amgen was one of the two companies ultimately selected, with its project designed to map out and measure the most efficient out-of-hospital administration methods for the Amgen drug Xgeva, prescribed to patients with advanced breast cancer.

The aim of this research will be to bring treatment closer to patients' homes and help health professionals decide the best treatment pathway for individual patients, rather than promoting Xgeva over any other similar medicine.

To take part in this project, Amgen agreed to meet the full cost of the project and spent time demonstrating its wider benefit to the NHS.

Rob Duncombe, director of pharmacy at The Christie and chair of the NHS Cancer Vanguard's joint medicines optimisation group, said: "We knew that the pharma industry had the best knowledge of how their medicines are used … and were delighted that so many offered time and resource to drive forward innovative projects."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.